Insights into the aetiology and pathogenesis of multiple sclerosis

Immunology and Cell Biology

Volumn 76, Issue 1, 1998, Pages 47-54

  Ewing, Christine ^a   Bernard, Claude C A ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis; MHC; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; T cells

Indexed keywords

GLYCOPROTEIN;

ARTICLE; AUTOIMMUNITY; DEMYELINATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; PROTEIN TARGETING;

ADULT; ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MYELIN PROTEINS; T-LYMPHOCYTES;

EID: 0031925248     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00718.x     Document Type: Article

References (104)

1. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: A critical overview. Can. J. Neurol. Sci. 1993; 20: 17-29.
2. Martyn C. Epidemiology. In: Matthews WB (ed.) Mc Alpine's Multiple Sclerosis, 2nd edn. Edinburgh: Churchill Livingstone, 1991; 3-40.
3. Lowis GW. The social epidemiology of multiple sclerosis. Sci. Total Environ. 1990; 90: 163-90.
4. Duquette P, Pleines J, Girard M et al. The increased susceptibility in women to multiple sclerosis. Can. J. Neurol. Sci. 1992; 19: 466-71.
5. Hallpike JF. Clinical aspects of multiple sclerosis, In: Hallpike JF, Adams CWM, Tourtellotte WW (eds). Multiple Sclerosis. London: Chapman and Hall, 1983: 129-61.
6. Tienari PJ. Multiple sclerosis: Multiple etiologies, multiple genes? Ann. Med. 1994; 26: 259-69.
7. Langdon DW, Thompson AJ. Cognitive problems in multiple sclerosis. MS Management 1996; 3: 1 & 7 9.
8. Martin R, Vogt AB, Kropshoefer H, Lichtenfels R. Association of HLA and multiple sclerosis. Behring Inst. Mitt. 1994; 94: 158-70.
9. Prineas JW. Pathology of the early lesion in multiple sclerosis. Hum. Pathol. 1975; 6: 531-54.
10. Raine CS. Multiple sclerosis: A pivotal role for the T-cell in lesion development. Neuropathol. Appl. Neurobiol. 1991; 17: 265-74.
11. Esiri MM. Multiple sclerosis: A quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. J. Neuropathol. Appl. Neurobiol. 1980; 6: 9-21.
12. Link H. Cerebrospinal fluid in immunological CNS diseases. In: Aarli JA, Behan WMH, Behan PO (eds). Clinical Neuroimmunology, London: Blackwell Science, 1987: 444-66.
13. Bernard CCA, Townsend E, Randell VB, Williamson HG. Do antibodies to myelin basic protein isolated from multiple sclerosis cross-react with measles and other common virus antigens? Clin. Exp. Immunol. 1983; 52: 98-106.
14. Panitch HS, Hooper CJ, Johnson KP. CSF antibody to myelin basic protein: Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch. Neurol. 1980; 37: 206-9.
15. Warren KG, Catz I, Johnson E, Bielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann. Neurol. 1994; 35: 280-9.
16. Kurtzke JF. Epidemiology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL. (eds). Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers BV, 1985; 259-87.
17. Acheson ED. The epidemiology of multiple sclerosis. In: Matthews WB, Acheson ED, Batchelor JR, Weiler RO (eds). McAlpine's Multiple Sclerosis. Edinburgh: Churchill Livingstone. 1985: 3-46.
18. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. Med. J. Aust. 1994; 160: 117-22.
19. Swingler RJ, Compston DAS. The distribution of multiple sclerosis in the United Kingdom. J. Neurol. Neurosurg. Psychiatry 1986; 49: 1115-24.
20. Skegg DCJ, Corwin PA, Craven RS et al. Occurrence of multiple sclerosis in north and south New Zealand. J. Neurol. Neurosurg. Psychiatry 1987; 50: 134-9.
21. Ebers GC, Bulman DE, Sadovnick AD et al. Population-based study of multiple sclerosis in twins. N. Engl. J. Med. 1986; 315: 1638-42.
22. Kinnunen E, Koskenvuo M, Kaprio J, Aho K. Multiple sclerosis in a nation-wide series of twins. Neurology 1987; 37: 1627-9.
23. Sadovnick AD, Armstrong H, Rice GP et al. A population-based study of multiple sclerosis in twins: Update. Ann. Neurol. 1993; 33: 281-5.
24. McFarland HF. Twin studies and multiple sclerosis. Ann. Neurol. 1993; 32: 722-3.
25. Sadovnick AD, Baird PA, Ward RA. Multiple sclerosis: Updated risks for relatives. Am. J. Med. Genet. 1988; 29: 533-41.
26. Doolittle TH, Myers RH, Lehrich JR et al. Multiple sclerosis and sibling pairs: Clustered onset and familial predisposition. Neurology 1990; 40: 1546-52.
27. Sadovnick AD, Bulman D, Ebers GC. Parent child concordance in multiple sclerosis. Ann. Neurol. 1991; 29: 252-5.
28. Wikstrom J. Studies on the clustering of multiple sclerosis in Finland. II: Microepidemiology in one high-risk county with special reference to familial cases. Acta Neurol. Scand. 1975; 51: 173-83.
29. Bertram J, Kuwert E. HLA antigen frequencies in multiple sclerosis. Eur. J. Neurol. 1982; 7: 74-9.
30. Tiwari JL, Terasaki PI. Multiple sclerosis. In: Tiwari JL, Terasaki PI (eds). HLA and Disease Associations. New York: Springer Verlag, 1985; 152-67.
31. Marrosu MG, Muntoni F, Murru MR et al. Sardinian multiple sclerosis is associated with HLA-DR4. Neurology 1988; 38: 1749-53.
32. Vartdal F, Sollid LM, Vandvik B et al. Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic amino acid sequences. Hum. Immunol. 1989; 25: 103-10.
33. Spurkland A, Ronningen KS, Vandvik B et al. HLA-DQA1 and HLA-DQB1 genes may jointly determine susceptibility to develop multiple sclerosis. Hum. Immunol. 1991; 30: 69-75.
34. Heard RNS, Cullen C, Middleton D et al. An allelic cluster of DQα restriction fragments is associated with multiple sclerosis: Evidence that a second haplotypc may influence disease susceptibility. Hum. Immunol. 1989; 25: 111-23.
35. Hammond SR, English D, Dewtit C et al. The clinical profile of MS in Australia: A comparison between medium-frequency and high-frequency prevalence zones. Neurology 1988; 38: 980-6.
36. Oskenberg JR, Stuart S, Begovich AB et al. Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients. Nature 1990; 345: 344-6.
37. Sherritt MA, Oskenberg J, Kerlero de Rosho N, Bernard CCA. Influence of HLA-DR2, HLA-DPw4, T-cell receptor α chain on the susceptibility to multiple sclerosis. Int. Immunol. 1992; 4: 177-81.
38. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. T-cell receptor Vα-Vβ repertoire and cytokine gene expression in active multiple sclerosis lesions. J. Exp. Med. 1992; 175: 993-1002.
39. + oligodendrocytes in multiple sclerosis. Proc. Natl Acad. Sci. USA 1991; 88: 6452-6.
40. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. γδ T-cell repertoire in acute multiple sclerosis lesions. Proc. Natl Acad. Sci. USA 1992; 89: 4588-92.
41. Hvas J, Oskenberg JR, Fernando R, Steinman L, Bernard CCA. γδ T-cell receptor repertoire in brain lesions of patients with multiple sclerosis. J. Neuroimmunol. 1993; 46: 225-34.
42. The Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nature Genet. 1996; 13: 469-71.
43. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet. 1996; 13: 464-8.
44. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nature Genet. 1996; 13: 472-6.
45. Oskenberg JR, Hauser SL. New insights into the immunogenetics of multiple sclerosis. Curr. Opin. Neural. 1997; 10: 181-5.
46. Bernard CCA, Mandel T, Mackay IR. Experimental models of human autoimmune disease: Overview and prototypes. In: Rose NR, Mackay IR (eds). The Autoimmune Diseases II. San Diego: Academic Press, 1992; 47-106.
47. Glynn P, Linington C. Cellular and molecular mechanisms of autoimmune demyelination in the central nervous system. CRC Crit. Rev. Neurobiol. 1989; 4: 367-87.
48. Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM (eds). Textbook of Neuropathology. Baltimore: Williams and Wilkins, 1990; 535-620.
49. Lebar R, Boutry J-M, Vincent C, Robineaux R, Voisin GA. Studies on autoimmune encephalomyelitis in the guinea pig. II: An in vitro investigation on the nature, properties and specificity of the serum demyelinating activity. J. Immunol. 1976; 116: 1439-46.
50. Lebar R, Vincent C. Studies on autoimmune encephalomyelitis in the guinea pig. IV: Relative dependence of acute and chronic diseases. Immunol. Lett. 1981; 2: 239-44.
51. Lebar R, Lubetski C, Vincent C, Lombrail P, Boutry J-M. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin. Exp. Immunol. 1986; 66: 423-43.
52. Linington C, Webb M, Woodhams P. A novel myelin-associated protein defined by a mouse monoclonal antibody. J. Neuroimmunol. 1984; 6: 387-96.
53. Gardinier MV, Amiguet P, Linington C, Matthieu J-M. Myelin/oligodendrocyte glycoprotein is a member of the immunoglobulin superfamily. J. Neurosci. Res. 1992; 33: 177-87.
54. Brunner C, Lassmann H, Waehneldt TV, Matthieu J-M, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendrocyte glycoprotein, and 2′, 3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J. Neurochem. 1989; 52: 296-304.
55. Kerlero de Rosbo N, Honegger P, Lassman H, Matthieu J-M. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin-oligodendrocyte glyco-protein (MOG). J. Neurochem. 1990; 55: 583-7.
56. Linington C, Bradl M, Lassman H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 1988; 130: 443-54.
57. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol. 1987; 139: 4016-21.
58. Linington C, Engelhardt B, Kapocs G, Lassman H. Induction of persistently demyelinated lesion in the rat following the repeated adoptive transfer of encephalitogenic T-cells and demyelinating antibody. J. Neuroimmunol. 1992; 40: 219-24.
59. Piddlesden SJ, Lassman H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 1993; 143: 555-64.
60. Adelmann M, Wood J, Benzel I et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J. Neuroimmunol. 1995; 63: 17-27.
61. Linington C, Berger T, Perry L et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 1993; 23: 1364-72.
62. Johns TG, Kerlero de Rosbo N, Menon KK, Abo S, Gonzales MF, Bernard CCA. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J. Immunol. 1995; 154: 5536-41.
63. Ichikawa M, Johns TG, Liu J, Bernard CCA. Analysis of the fine B-cell specificity during the chronic relapsing course of a multiple sclerosis-like disease in Lewis rats injected with encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J. Immunol. 1996; 157: 919-26.
64. Ichikawa M, Johns TG, Adelmann M, Bernard CCA. Antibody response in Lewis rats injected with myelin oligodendrocyte glycoprotein-derived peptides. Int. Immunol. 1997; 8: 1667-74.
65. Bernard CCA. Experimental autoimmune encephalomyelitis in mice: Genetic control of susceptibility. J. Immunogenet. 1976; 3: 263-74.
66. Bernard CCA, Johns TG, Slavin A et al. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 1997; 75: 77-88.
67. Slavin A, Ewing C, Ichikawa M, Liu J, Slavin J, Bernard CCA. Induction of a multiple sclerosis-like disease in NOD Lt and C57BL/6 mice by immunization with an immundominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 1998 (in press).
68. Adams CWM. The general pathology of multiple sclerosis: Morphological and chemical aspects of the lesions. In: Hallpike JF, Adams CWM, Tourtellotte WW (eds). Multiple Sclerosis: Pathology, Diagnosis and Management. London: Chapman and Hall, 1983; 203-40.
69. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 1995; 32: 121-82.
70. Martin R, Jaraquemada D, Flerlage M et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 1990; 145: 540-48.
71. Pette M, Fujita K, Kitze B et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770-6.
72. Jingwu Z, Mcdaer R, Hashim GA, Chin Y, vanden Berg-Loonen E, Raus J. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity and cytotoxicity. Ann. Neurol. 1992; 32: 330-8.
73. Meinl E, Weber F, Drexler K et al. Myelin basic protein-specific lymphocyte repertoire in multiple sclerosis: Complexity of the response and dominance of nested epitopes due to recruitment of multiple T-cell clones. J Clin. Invest. 1993; 92: 2633-43.
74. Martin R, Howell MD, Jaraquemada D et al. A myelin basic protein peptide is recognized by cytotoxic T-cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 1991; 173: 385-93.
75. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-7.
76. Wucherpfennig KW, Sette A, Southwood S et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T-cell clones. J. Exp. Med. 1994; 179: 279-90.
77. Vogt AB, Kropshofer H, Kalbacher H et al. Ligand motifs of HLA DR5*0101 and DRB1*1501 molecules delineated from self peptides. J. Immunol. 1994; 153: 1665-73.
78. Morimoto C, Hafler DA, Weiner HL et al. Selective loss of the suppressor inducer T-cell subset in progressive multiple sclerosis. N. Engl. J. Med. 1987; 316: 67-72.
79. Hintzen RQ, Polman CH, Lucas CJ, van Lier RAW. Multiple-sclerosis: Immunological findings and possible implications for therapy. J. Neuroimmunol. 1992; 39: 1-10.
80. Zhang JW, Markovic S, Lacet B, Raus J, Weiner HW, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 1994; 179: 973-84.
81. Wucherpfennig KW, Ota K, Endo N et al. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 1990; 248: 1016-19.
82. Fugger L, Sandberg-Wollheim M, Morling N, Ryder L, Svejgaard A. The germline repertoire of T-cell receptor β chain genes in patients with relapsing/remitting multiple sclerosis or optic neuritis. Immunogenetics 1990; 31: 278-80.
83. Martin R, Utz U, Coligan JE et al. Diversity in fine specificity and T cell receptor usage of the human cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 1992; 148: 1359-66.
84. Giegerich G, Pette M, Meinl E et al. Diversity of T cell receptor α and β chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes. Eur. J. Immunol. 1992; 22: 753-8.
85. Allegretta M, Albertini RJ, Howell MD et al. Homologics between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J. Clin. Invest. 1994; 94: 105-9.
86. Kondo T, Yamamura T, Inobe J, Ohashi T, Takahashi K, Tabira T. TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): Homologics between PLP-specific T cells and MS-associated T cells in TCR junctional sequences. Int. Immunol. 1996; 8: 123-30.
87. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. J. Clin. Invest. 1993; 92: 2602-8.
88. Abo S, Bernard CCA, Webb M et al. Preparation of highly purified human myelin oligodendrocyte glycoprotein in quantities sufficient for encephalitogenicity and immunogenicity studies. Biochem. Mol. Biol. Int. 1993; 30: 945-58.
89. Sun J, Link H, Olsson T et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 1991; 146: 1490-5.
90. Hartung HP. Pathogenesis of multiple sclerosis. In: Abramsky O, Ovadia H (eds). Frontiers in Multiple Sclerosis. London: Martin Dunitz Ltd, 1997; 45-59.
91. Vergelli M, Pinel V, Vogt AB et al. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. Eur. J. Immunol. 1997; 27: 941-51.
92. Voskuhl RR, Martin R, Bergman C et al. T helper I (TH1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993; 15: 137-43.
93. Olsson T, Wei Zhi W, Hojeberg B et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ J. Clin. Invest. 1990; 86: 981-5.
94. Vartanian T, Li Y, Zhao M, Stefansson K. Interferon-γ-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis. Mol. Med. 1995; 1: 732-43.
95. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma-interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-102.
96. Selmaj KW, Raine CS. Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1988; 23: 339-46.
97. Olsson T. Immunology of multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 1992; 5: 195-202.
98. Liu J, Marino M, Wong G et al. TNF is a potent antiinflammatory cytokine in autoimmune mediated demyelination. Nature Med. 1998 (in press).
99. Vanoosten BW, van Oosten BW, Barkhoff F et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumour necrosis factor antibody CA2. Neurology 1996; 47: 1531-4.
100. Waksman BH. Multiple sclerosis. Curr. Opin. Immunol. 1989; 1: 733-9.
101. Rohowsky-Kochan C, Dowling P, Cook SD. Canine distemper virus-specific antibodies in multiple sclerosis. Neurology 1995; 45: 1554-60.
102. Challoner PB, Smith KT, Parker JD et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl Acad. Sci. USA 1995; 92: 7440-4.
103. Sibley WA, Bamford CR, Clark K et al. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-15.
104. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.